Imatinib Resistance and Progression of CML to Blast Crisis: Somatic Hypermutation AIDing the Way  by Strout, Matthew P. & Schatz, David G.
DeNardo, D.G., Barreto, J.B., Andreu, P., Vasquez,
L., Tawfik, D., Kolhatkar, N., and Coussens, L.M.
(2009). Cancer Cell 16, 91–102.
Fridlender, Z.G., Sun, J., Kim, S., Kapoor, V.,
Cheng, G., Ling, L., Worthen, G.S., and Al-
belda, S.M. (2009). Cancer Cell 16, this issue,
183–194.
Gabrilovich, D.I., and Nagaraj, S. (2009). Nat. Rev.
Immunol. 9, 162–174.
Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li,
N.F., Pluddemann, A., Charles, K., Gordon, S.,
and Balkwill, F.R. (2006). J. Immunol. 176, 5023–
5032.
Mantovani, A., Sozzani, S., Locati, M., Allavena, P.,
and Sica, A. (2002). Trends Immunol. 23, 549–555.
Mantovani, A., Allavena, P., Sica, A., and Balkwill,
F. (2008). Nature 454, 436–444.
Nozawa, H., Chiu, C., and Hanahan, D. (2006).
Proc. Natl. Acad. Sci. USA 103, 12493–12498.
Pekarek, L.A., Starr, B.A., Toledano, A.Y., and
Schreiber, H. (1995). J. Exp. Med. 181, 435–440.
Pollard, J.W. (2004). Nat. Rev. Cancer 4, 71–78.
Yang, L., Huang, J., Ren, X., Gorska, A.E., Chytil,
A., Aakre, M., Carbone, D.P., Matrisian, L.M., Rich-
mond, A., Lin, P.C., and Moses, H.L. (2008).
Cancer Cell 13, 23–35.
Cancer Cell
PreviewsImatinib Resistance and Progression
of CML to Blast Crisis:
Somatic Hypermutation AIDing the Way
Matthew P. Strout1 and David G. Schatz2,3,*
1Yale Cancer Center, Department of Internal Medicine, Section of Hematology
2Department of Immunobiology
3Howard Hughes Medical Institute
Yale University School of Medicine, New Haven, CT 06520, USA
*Correspondence: david.schatz@yale.edu
DOI 10.1016/j.ccr.2009.08.012
Very little is known about how acquired oncogenic mutations arise. In this issue of Cancer Cell, Klemm and
colleagues present evidence supporting a role for the antibody diversification enzyme activation-induced
deaminase (AID) in the generation of mutations associated with disease progression and drug resistance
in chronic myeloid leukemia.Chronic myeloid leukemia (CML) is a
clonal disease of hematopoietic stem
cells (HSCs) that occurs as a result of a
reciprocal translocation between chro-
mosomes 9 and 22 (Quintas-Cardama
and Cortes, 2009). This rearrangement
gives rise to the Philadelphia (Ph) chromo-
some that, at the molecular level, con-
tains a genomic fusion between the
BCR gene from chromosome 22 and the
ABL1 gene from chromosome 9. ABL1
encodes the Abelson tyrosine kinase,
and its enforced expression from the
BCR-ABL1 gene fusion drives the patho-
genesis of Ph+ leukemias through phos-
phorylation of a wide range of substrates
that regulate cell proliferation, differentia-
tion, migration, survival, and DNA repair.
Clinically, CML follows a triphasic course,
with the majority of patients presenting in
chronic phase characterized by an accu-
mulation of myeloid progenitor cells and
mature granulocytes in the bone marrow174 Cancer Cell 16, September 8, 2009 ª20and peripheral blood. If untreated, the
chronic phase can last several years be-
fore progressing to an accelerated phase
characterized by increasing disease bur-
den and frequently accompanied by the
acquisition of additional genetic defects.
The accelerated phase can last weeks to
months and signals the imminent devel-
opment of blast crisis, the final phase of
CML. Clinically, blast crisis behaves like
acute leukemia and can have an immature
myeloid, pre-B lymphoblastic, or mixed-
lineage phenotype (Garcia-Manero et al.,
2003). The molecular mechanisms in-
volved in the evolution of this complex
disease from chronic phase to blast crisis
remain largely unknown, although it is
clear that genetic changes in addition to
the Ph chromosome are required.
Approved by the FDA in 2001, the tyro-
sine kinase inhibitor imatinib was the
first drug to be designed specifically to
target a molecular defect associated with09 Elsevier Inc.cancer and has revolutionized the man-
agement of CML. Imatinib binds to the
catalytic domain of the ABL1 kinase, pre-
venting ATP binding and trapping it in
an inactive conformation (Druker, 2008).
Newly diagnosed chronic-phase CML pa-
tients treated with imatinib demonstrated
a complete hematologic response of
96% at one year and an overall survival
of 89% at five years (Druker et al., 2006).
However, approximately 6% of chronic-
phase patients relapse and develop resis-
tance to imatinib and many patients who
are first treated during accelerated phase
or blast crisis demonstrate imatinib resis-
tance (Druker, 2008). In the majority of
cases, imatinib resistance is due to point
mutations in BCR-ABL1 that change the
conformation of the ABL1 kinase domain,
preventing imatinib binding. Many of
these mutations can be overcome by
treatment with next-generation tyrosine
kinase inhibitors such as dasatinib or
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Previewsnilotinib, but one mutation, T315I, causes
complete insensitivity to all currently avail-
able tyrosine kinase inhibitors and is
present in approximately 15% of patients
after failure of imatinib therapy (Quintas-
Cardama and Cortes, 2009). Under-
standing how this and other BCR-ABL1
mutations arise is of considerable clinical
importance.
In this issue of Cancer Cell, Klemm
and colleagues provide multiple lines of
evidence supporting a role for the activa-
tion-induced deaminase (AID) in the pro-
gression of CML to lymphoid blast crisis
(CML-LBC) and the generation of BCR-
ABL1mutations that confer imatinib resis-
tance (including T315I) (Klemm et al.,
2009). AID is a DNAmutator that functions
in antigen-activated mature B cells to
trigger somatic hypermutation and class
switch recombination of immunoglobulin
genes (Di Noia and Neuberger, 2007). It
is a dangerous enzyme whose aberrant
expression or targeting has been impli-
cated in translocations and point muta-
tions of proto-oncogenes associated with
a variety of B cell malignancies (Okazaki
et al., 2007; Tsai et al., 2008). However,
as a protein expressed primarily in mature
B cells, how could AID contribute to the
pathogenesis of a myeloid disorder?
Klemm et al. (2009) demonstrate that
although AID is absent in chronic-phase
CML, it is expressed and active in a subset
of patients with CML-LBC. Analysis of
human CML-LBC cells as well as BCR-
ABL1-transformed mouse B cell progeni-
tors strongly implicate AID in both the
generation of point mutations and copy
number alterations in a variety of genes.
Furthermore, the data suggest that upre-
gulation of AID in these cells occurs in
the absence of several protective mecha-
nisms (e.g., the upregulation of DNA
repair factors such as ATM and BRCA1)
that would normally operate in activated
mature B cells. Several of the genes with
copy number alterations encode proteins
involved in DNA repair, DNA damage sig-
naling, or cell cycle control, suggesting
direct and indirect roles for AID in genome
instability and the pathogenesis of CML-
LBC.
Klemm et al. (2009) also strongly impli-
cate AID in the generation of BCR-ABL1
point mutations and the development
of imatinib resistance. AID-expressing
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Figure 1. Model of CML Evolution, Lineage Conversion, and Acquisition of Imatinib-
Resistant BCL-ABL1 Mutations
In chronic-phase CML, differentiation of a Ph+ HSC along themyeloid lineage predominates, with >95% of
circulating Ph+ cells being mature granulocytes. The remaining cells differentiate along the B lymphoid
lineage, giving rise to a small population of mature Ph+ B cells. However, in Ph+ B lymphoid progenitors,
expression of PAX5 can lead to upregulation of AID with aberrant somatic hypermutation of BCR-ABL1
and acquisition of imatinib resistance. Lineage conversion from B lymphoid progenitor to myeloid progen-
itor (or differentiation of a PAX5 and AID-expressing CMLHSC along themyeloid lineage) would allow AID-
generated mutations to appear in myeloid cells. Blast crisis subsequently evolves from a Ph+ B lymphoid,
mixed-lineage, or myeloid progenitor that contains additional genetic alterations.Cancer Cell 16,tive counterparts, exhibited selective out-
growth in the presence of imatinib and
the acquisition of BCR-ABL1 mutations
frequently found in patients with imati-
nib-resistant disease, including T315I.
Collectively, the findings indicate that in
AID-expressing BCR-ABL1-transformed
B cells, genomic stability is compromised
by the combined effects of DNA repair
deficits and ongoing somatic hypermuta-
tion, and that this contributes to the acqui-
sition of imatinib resistance throughmuta-
tion of BCR-ABL1.
Imatinib resistance resulting from BCR-
ABL1 kinase domain mutations is not
exclusive to CML-LBC and is also found
in patients with chronic-phase CML and
myeloid blast crisis (CML-MBC), yet these
cells do not express AID. Although some
of these mutations likely arise in an AID-
independent manner, AID might con-
tribute to the generation of others, either
through its action in a CML progenitor or
through the phenomenon of lineage con-
version (Figure 1). CML cells likely origi-
nate from a HSC with self-renewal ca-
pacity and the ability to differentiate into
multiple lineages (Takahashi et al., 1998),
particularly the myeloid and B lymphoid
lineages. PAX5 is a transcription factor
important for B cell lineage commitment
and AID expression, and in a key experi-
ment, Klemm et al. (2009) demonstrate
that ectopic expression of PAX5 in CML
cell lines of myeloid origin is sufficient to
induce myeloid to B lymphoid lineage
conversion with expression of B cell-
specific markers, recombination of im-
munoglobulin genes, and upregulation of
AID. Significantly, these cells acquire
mutations in the BCR-ABL1 kinase do-
main and imatinib resistance. Thus, as
Klemm et al. (2009) point out, it is possible
that imatinib-resistant Ph+ myeloid cells
andCML-MBCsometimesariseasaresult
of PAX5-dependent oscillations between
the myeloid and B lymphoid lineages (Yu
et al., 2003), with the critical BCR-ABL1
mutations occurring in an AID-dependent
manner in PAX5-expressing B lymphoid
cells (Figure 1). This model is supported
by their finding that many primary cases
of CML-MBC contain rearranged and
mutated immunoglobulin genes (Klemm
et al., 2009). This model and the findings
of Klemm et al. (2009) suggest that it is
important to minimize the number of Ph+
B lymphoid lineage cells in CML patients,
a goal that might be undermined bySeptember 8, 2009 ª2009 Elsevier Inc. 175
Cancer Cell
Previewsinterruptions in tyrosine kinase inhibitor
treatment (resulting from either medica-
tion noncompliance or intolerance).
This study introduces AID and immune
diversificationmechanisms into thealready
complex biology of CML. Future investiga-
tions into the role of AID and BCR-ABL1
in causing tyrosine kinase inhibitor resis-
tance, genomic instability, andprogression
to blast crisis will be important for under-
standing the pathogenesis of the disease
as well as for developing therapeutic inter-
ventions to prevent these processes. Addi-
tional insight is likely to be gained through
investigations into the multilineage dy-Src Substrate Sur
G. Steven Martin1,*
1Department of Molecular and Cell Biology an
*Correspondence: gsm@berkeley.edu
DOI 10.1016/j.ccr.2009.08.017
In this issue of Cancer Cell, Lowy an
phorylation by Src and that this pho
tion of the SH2 domain represents a
Src is a nonreceptor tyrosine kinase that
is activated by a variety of mechanisms
in human cancer. Its biological effects
are mediated by the phosphorylation of a
plethora of protein substrates. A primary
role of tyrosine phosphorylation is to
generate docking sites for proteins con-
taining SH2 or PTB domains, thereby
promoting protein-protein interactions
and the formation of macromolecular
complexes that function in intracellular
signal transduction (Pawson, 2004). The
binding activity of SH2 domains is pri-
marily regulated by the phosphorylation
of the ligand, although some SH2 domain-
target interactions are phosphorylation
independent.
Many prominent Src substrates are
found at focal adhesions, including the
focal adhesion kinase FAK and the Crk-
associated substrate Cas. Focal adhe-
sions are sites of integrin-dependent
substrate adhesion generated by Rho-
ROCK-activated actomyosin-dependent
contractility. They serve as sites for the
176 Cancer Cell 16, September 8, 2009 ª20namics of the CML HSC and factors that
regulate expression of PAX5 and AID.
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Tensins are another family of focal
adhesion proteins that can serve as Src
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the family in mammals (Lo, 2004). Tensins
1–3 contain three distinct regions (Fig-
ure 1A): the N-terminal domains bind to
the side of F-actin and target themolecule
to focal adhesions, and the central region
of the tensins is nonconserved, whereas
the C terminus contains an SH2 domain
and a PTB domain. The PTB domain inter-
acts, not with tyrosine phosphorylated
proteins, but with NPXY motifs in the
integrin tails of b1, 3, 5, and 7. Tensin-1
null fibroblasts show migration defects,
and the focal adhesion localization and
SH2 domains of tensin-1 are required
for this promigratory function (Chen
and Lo, 2003). The tensin SH2 domain
binds to tyrosine-phosphorylated Cas
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and FAK, which are pro-oncogenic.
However, it also binds to nonphosphory-
lated RhoGAP7, aka DLC1 (deleted in
liver cancer 1), a focal adhesion-localized
protein that is a known tumor suppressor,
and to the related tumor suppressor DLC3
(Liao et al., 2007; Qian et al., 2007).
Perhaps consistent with the fact that
tensins interact with both pro- and antion-
cogenic proteins, expression profiling and
overexpression studies have supported
both pro- and antioncogenic functions
for tensins. In addition, the oncogenic
functions of tensins may be isoform
specific (Yam et al., 2006; Katz et al.,
2007). Intrigued by this complexity, Qian
et al. (2009) decided to examine the
functions of different tensins in both Src-
transformed fibroblasts and a panel of
human cancer cell lines. Knockdown of
tensin-3 inhibited transformation by Src
and cell migration and growth of the
human cancer lines. These effects were
not observed upon knockdown of the
other tensin family members. In addition,
